These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8060901)

  • 1. Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy?
    Newell DR
    Ann Oncol; 1994; 5 Suppl 4():9-14; discussion 15. PubMed ID: 8060901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship].
    Canal P; Chatelut E
    Bull Cancer; 1996 Apr; 83(4):256-65. PubMed ID: 8680077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic studies in children with cancer.
    Groninger E; Proost JH; de Graaf SS
    Crit Rev Oncol Hematol; 2004 Dec; 52(3):173-97. PubMed ID: 15582785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacodynamics of anticancer agents].
    Ohtsu T; Sasaki Y
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1741-9. PubMed ID: 8379667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetically guided administration of chemotherapeutic agents.
    van den Bongard HJ; Mathôt RA; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2000 Nov; 39(5):345-67. PubMed ID: 11108434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
    Petit-Jean E; Buclin T; Guidi M; Quoix E; Gourieux B; Decosterd LA; Gairard-Dory AC; Ubeaud-Séquier G; Widmer N
    Ther Drug Monit; 2015 Feb; 37(1):2-21. PubMed ID: 24831652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.
    Lucas CJ; Martin JH
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S78-S98. PubMed ID: 28921641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalizing chemotherapy dosing using pharmacological methods.
    Patel JN; Papachristos A
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):879-96. PubMed ID: 26298089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
    Loh GW; Ting LS; Ensom MH
    Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer drug pharmacodynamics.
    Powis G
    Cancer Chemother Pharmacol; 1985; 14(3):177-83. PubMed ID: 3888428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of high-dose chemotherapy.
    Nieto Y
    Curr Drug Metab; 2001 Mar; 2(1):53-66. PubMed ID: 11465151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
    Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
    Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
    Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anticancer drug dose individualisation: from body surface area to physiology].
    Pétain A; Chatelut E
    Bull Cancer; 2008 Oct; 95(10):895-901. PubMed ID: 19004718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children.
    Rodman JH; Relling MV; Stewart CF; Synold TW; McLeod H; Kearns C; Stute N; Crom WR; Evans WE
    Semin Oncol; 1993 Feb; 20(1):18-29. PubMed ID: 8475406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
    Fujita K; Sasaki Y
    Drug Metab Pharmacokinet; 2014; 29(1):20-8. PubMed ID: 24256625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity.
    Evans WE
    Blut; 1988 Jun; 56(6):241-8. PubMed ID: 3289632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.